Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M33.5Revenue (TTM) $M0.7Net Margin (%)-6,168.5Altman Z-Score-10.0
Enterprise Value $M0.6EPS (TTM) $-22.8Operating Margin %-4,565.1Piotroski F-Score3
P/E(ttm)--Beneish M-Score3.3Pre-tax Margin (%)-6,194.4Higher ROA y-yN
Price/Book2.110-y EBITDA Growth Rate %--Quick Ratio6.5Cash flow > EarningsY
Price/Sales11.35-y EBITDA Growth Rate %-39.5Current Ratio6.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-83.0Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-272.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M9.9ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with AEZS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AEZSFirst Eagle Investment 2010-03-31 Sold Out $474 - $558.06
($499.42)
$ 3.37-99%Sold Out0
AEZSFirst Eagle Investment 2009-12-31 Reduce-0.02%$473.4 - $750
($607.39)
$ 3.37-99%Reduce -91.09%208
AEZSFirst Eagle Investment 2009-09-30 Buy 0.02%$534 - $1698
($960.59)
$ 3.37-100%New holding2,330
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AEZS is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


AEZS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ernst, JrgenDirector 2014-11-12Buy600$60-94.38view
Ernst, JrgenDirector 2014-11-12Buy394$61.79-94.55view
Ernst, JrgenDirector 2014-11-12Buy76$61.49-94.52view
Ernst, JrgenDirector 2014-11-12Buy31$61.4-94.51view
Ernst, JrgenDirector 2014-11-12Buy149$61.46-94.52view
Dodd, David AlanDirector, Senior Officer 2014-11-10Buy85$56.5-94.04view
Dodd, David AlanDirector, Senior Officer 2014-11-10Buy10$56.97-94.08view
Dodd, David AlanDirector, Senior Officer 2014-11-10Buy344$57-94.09view
Dodd, David AlanDirector, Senior Officer 2014-11-10Buy30$57.5-94.14view
Dodd, David AlanDirector, Senior Officer 2014-11-10Buy1,281$58-94.19view

Quarterly/Annual Reports about AEZS:

    News about AEZS:

    Articles On GuruFocus.com
    Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
    Can Keryx Succeed Without Partnership? Apr 24 2012 
    Keryx Still Has High Potential from Zerenex Apr 12 2012 
    Opportunistic Coat-tailing Jan 05 2010 

    More From Other Websites
    07.27.2016 Aeterna Zentaris to Announce Second Quarter 2016 Financial and Operating Results on... Jul 27 2016
    Aeterna Zentaris to Announce Second Quarter 2016 Financial and Operating Results on August 9, 2016 Jul 27 2016
    07.01.2016 Aeterna Zentaris and Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement for... Jul 01 2016
    Aeterna Zentaris and Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement for Zoptrex™ in... Jul 01 2016
    Aeterna Zentaris and Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement for Zoptrex™ in... Jul 01 2016
    05.23.2016 Aeterna Zentaris Elects Ms. Carolyn Egbert as Independent Chair of the Board Jun 16 2016
    06.06.2016 Aeterna Zentaris Reconfirms Commitment to LHRH-receptor Targeting Zoptrex™ During 2016... Jun 16 2016
    06.14.2016 Aeterna Zentaris Announces IND Submission by Sinopharm A-Think Jun 16 2016
    Aeterna Zentaris Announces IND Submission by Sinopharm A-Think Jun 14 2016
    Aeterna Zentaris Reconfirms Commitment to LHRH-receptor Targeting Zoptrex™ During 2016 ASCO Annual... Jun 06 2016
    Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 Jun 02 2016
    Aeterna Zentaris Elects Ms. Carolyn Egbert as Independent Chair of the Board May 23 2016
    Aeterna Zentaris Announces Election of Directors at 2016 Shareholders' Meeting May 10 2016
    Aeterna Zentaris reports 1Q loss May 09 2016
    Aeterna Zentaris reports 1Q loss May 09 2016
    Aeterna Zentaris Reports First Quarter 2016 Financial and Operating Results May 09 2016
    Aeterna Zentaris Acquires Exclusive U.S. Promotional Rights for APIFINY® Prostate Cancer Blood Test Apr 27 2016
    Aeterna Zentaris to Announce First Quarter 2016 Financial and Operating Results on May 9, 2016 Apr 26 2016
    Aeterna Zentaris Mails Information Circular in Connection with Annual Meeting of Shareholders Apr 08 2016
    AETERNA ZENTARIS INC. Financials Apr 02 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)